Charles River Laboratories International, Inc.
CRL
$138.79
-$2.57-1.82%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.17% | -214.65% | -20.29% | -3.03% | -34.72% |
| Total Depreciation and Amortization | -0.58% | 15.14% | 11.83% | 10.83% | 10.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 137.51% | 480.45% | -39.14% | 0.57% | 19.72% |
| Change in Net Operating Assets | 102.68% | -210.44% | 2,997.53% | 77.84% | 47.69% |
| Cash from Operations | 32.19% | -27.87% | 22.56% | 30.66% | 18.75% |
| Capital Expenditure | 25.04% | 3.46% | 41.28% | 41.40% | 25.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.91% | 96.84% | 227.83% | -83.19% | 42.58% |
| Cash from Investing | 46.99% | 68.07% | 73.20% | 19.24% | 49.12% |
| Total Debt Issued | 38.37% | -76.36% | 359.78% | 393.10% | 56.30% |
| Total Debt Repaid | 48.92% | 44.89% | -54.14% | -335.05% | -85.91% |
| Issuance of Common Stock | -- | -87.07% | -80.22% | -78.97% | 82.37% |
| Repurchase of Common Stock | -3,676.41% | 10.79% | -265,126.32% | -79.50% | 50.82% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -766.85% | 5.06% | -224.87% | -- | 18.55% |
| Cash from Financing | -674.10% | -161.41% | -27.43% | -300.00% | -27.32% |
| Foreign Exchange rate Adjustments | 162.78% | -205.70% | 224.50% | -1,950.31% | -601.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -51.61% | -105.11% | 170.98% | -138,085.09% | 267.23% |